H.C. Wainwright analyst Andrew Fein upgraded Terns Pharmaceuticals (TERN) to Buy from Neutral with a $20 price target
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TERN:
- Terns Pharmaceuticals price target raised to $27 from $14 at Barclays
- Terns Pharmaceuticals price target raised to $22 from $15 at BMO Capital
- Terns Pharmaceuticals price target raised to $35 from $28 at Jefferies
- Enliven being 20% down on Terns news ‘makes no sense,’ says Mizuho
- Midday Fly By: AWS in deal with OpenAI, Kimberly-Clark to buy Kenvue